CompletedEUCTR 2015-004483-11
Raloxifene Augmentation in Patients with a Schizophrenia spectrum Disorder to reduce symptoms and improve cognition
This historical record does not confirm current site availability.
Historical research recordBelgium + Netherlands
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
- Listed locations
- Belgium · Netherlands
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 154
- Sponsor
- University Medical Center Utrecht
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Belgium, Netherlands
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2015-004483-11
- Official title
Show the full official title
Raloxifene Augmentation in Patients with a Schizophrenia spectrum Disorder to reduce symptoms and improve cognition
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium · Netherlands
Registry details
Historical country statuses
- Belgium — Completed
- Netherlands — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Medical Center Utrecht, a hospital or academic medical center.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication